Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC cut its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 1.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,371,562 shares of the biopharmaceutical company’s stock after selling 17,452 shares during the quarter. Fisher Asset Management LLC owned 1.05% of Dynavax Technologies worth $15,279,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its holdings in Dynavax Technologies by 175.5% during the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 1,685 shares in the last quarter. US Bancorp DE lifted its holdings in Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 2,034 shares in the last quarter. Capital Performance Advisors LLP acquired a new stake in Dynavax Technologies during the 3rd quarter worth approximately $45,000. Nisa Investment Advisors LLC lifted its holdings in Dynavax Technologies by 44.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 1,679 shares in the last quarter. Finally, Algert Global LLC acquired a new stake in Dynavax Technologies during the 2nd quarter worth approximately $140,000. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Price Performance

Shares of DVAX opened at $12.91 on Thursday. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The firm’s fifty day simple moving average is $11.59 and its 200-day simple moving average is $11.36. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of 99.32 and a beta of 1.34. Dynavax Technologies Co. has a twelve month low of $9.74 and a twelve month high of $15.01.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. The Goldman Sachs Group reduced their price objective on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. HC Wainwright restated a “buy” rating and issued a $29.00 price objective on shares of Dynavax Technologies in a report on Friday, November 8th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.